Accolade

Accolade, Inc. engages in the provision of personalized health and benefits solutions. Its products include Accolade Total Benefits, which is designed for employers with low employee adoption of healthcare and benefits programs, Accolade Total Care, which focuses on influencing the actual interactions between employees and providers, and are also interested in care management services, and Accolade Total Health and Benefits, which offers a full suite of solutions. The company was founded by Thomas K. Spann, J. Michael Cline, and Sudhir Steven Singh in 2007 and is headquartered in Seattle, WA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Accolade reports strong Q4 performance, faces market challenges ahead

Accolade's transformation into a personalized healthcare company has shown strong growth and improved financial performance. The company faces challenges related to operational excellence, market strategy, and the impact of industry decisions. However, opportunities lie in leveraging technology for healthcare and the upcoming Capital Markets Day to showcase growth prospects.

Accolade exceeds Q3 revenue guidance, eyes profitability by fiscal '25

Accolade's Q3 earnings call highlighted strong performance, diverse customer relationships, and growth opportunities in government business and virtual care. The company aims to achieve profitability by fiscal '25 through strategic investments and operational improvements, leveraging its competitive advantage in delivering ROI and performance guarantees.

Accolade reports robust Q4 performance, eyes tech-driven growth opportunities

Accolade's Q4 2023 Earnings Call highlighted strong financial performance, customer focus, and strategic initiatives. The company faces challenges in timing performance guarantees but sees opportunities in technology adoption and growth strategies.

Accolade surpasses Q1 expectations, eyes growth in healthcare partnerships

Accolade's Q1 performance exceeded expectations, with a focus on growth drivers and streamlining decision-making. Despite challenges in the government business, the company is optimistic about future growth opportunities and customer acquisition. Improved guidance and a strong pipeline indicate a positive outlook for the year.

Accolade beats Q2 revenue targets, eyes profitability in fiscal '25

Accolade exceeded revenue and EBITDA expectations in Q2, driven by strong customer additions and unique service offerings. Despite challenges from drug impacts and contract disputes, the company maintains its full-year guidance and eyes profitability in fiscal '25.

Accolade excels in Q3, eyes automation for growth opportunities

Accolade's Q3 performance exceeded expectations, with a positive outlook for future revenue and EBITDA. Differentiation in services and technology integration drive operational excellence. Uncertainty around TRICARE contract and focus on automation and growth opportunities.

Accolade reports robust Q4 earnings, eyes sustainable growth in '25

Accolade's strong performance in Q4 2024 sets a positive trajectory for fiscal year '25, with a focus on sustainable growth and profitability. The company's strategic strengths in serving a large customer base, successful partnerships, and innovative offerings position it well for future opportunities despite challenges in meeting revenue guidance and addressing post-security breach concerns.

Accolade reports strong Q2 earnings, focuses on profitability and growth

Accolade's Q2 performance exceeded expectations, emphasizing profitability and member experience.
The company's strengths lie in revenue growth, cost management, and competitive wins.
Challenges include cost structure management and balancing growth with profitability.
Opportunities exist in enhancing member experience, expanding partnerships, and driving sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann and J. Michael Cline in January 2007 and is headquartered in Seattle, WA.

The consensus price target hints at a 26.9% upside potential for Accolade (ACCD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 26.85% Upside in Accolade (ACCD): Here's What You Should Know

Accolade (ACCD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Accolade (ACCD) Stock Might be a Great Pick

I continue to recommend a buy rating with a projected 20% growth in FY25. Recent results show that Accolade beat consensus estimates for revenue and EBITDA, and management expects 20% revenue growth and 2-4% EBITDA margins in FY25. Tailwinds for growth include strong demand for navigation solutions, the health plan channel strategy, GLP-1 growth catalyst, and the recovery in demand for expert medical opinion.

Accolade: Remain Confident That FY25 Guided Growth Is Achievable

Accolade, Inc. (ACCD) Q3 2024 Earnings Call Transcript

SEATTLE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal third quarter ended November 30, 2023.

Accolade Announces Results for Fiscal Third Quarter 2024

LONDON, January 04, 2023 – Avenir LNG Limited (“Avenir”) today announces it has executed two Time Charter Agreements for the Avenir Advantage and the Avenir Accolade.

Avenir LNG secures time charter extensions for Avenir Advantage and Avenir Accolade

Accolade (ACCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Accolade (ACCD) Report Negative Earnings Next Week? What You Should Know

SANTA MONICA, CA / ACCESSWIRE / December 7, 2023 / License Global, the premier publication and leading source of news and trends for the global consumer product and licensing industries, has released the 2023 edition of The Influentials, celebrating leaders in the business of brand licensing who have driven change and advanced the global consumer product industry. The feature recognizes professionals across nine categories, each designed to spotlight an extraordinary individual who has moved the needle within the brand licensing industry.

License Global Releases 2023 Annual Accolade, The Influentials

Here is how Accolade (ACCD) and Adecco SA (AHEXY) have performed compared to their sector so far this year.

Is Accolade (ACCD) Stock Outpacing Its Business Services Peers This Year?

SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Piper Sandler 35th Annual Healthcare Conference in New York on Wednesday, November 29, 2023 at 10:00 am ET. A webcast of the company's fireside chat will be available at ir.accolade.com and a replay will be available for 90 days.

Accolade To Present at Piper Sandler 35th Annual Healthcare Conference

SEATTLE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it has entered into separate, privately negotiated transactions with certain holders of its outstanding 0.50% Convertible Senior Notes due 2026 (the “Notes”) to repurchase (the “Repurchases”) approximately $76.5 million aggregate principal amount of the Notes for an aggregate cash repurchase price of approximately $65.8 million.

Accolade Announces Repurchase of $76.5 Million of 0.50% Convertible Senior Notes Due 2026

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Stephen Annual Investment Conference in Nashville on Wednesday, November 15, 2023 at 11:00am CT. A webcast of the company's fireside chat will be available at ir.accolade.com and a replay will be available for 90 days.

Accolade To Present at Stephens Annual Investment Conference

Attributes 227% revenue growth to a relentless focus on delivering exceptional outcomes SEATTLE , Nov. 8, 2023 /PRNewswire/ -- Accolade today announced it has been named to the Deloitte Technology Fast 500™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year. Accolade grew 227% during this period.

Accolade Named to 2023 Deloitte Technology Fast 500™

Accolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -31.39% in 4 Weeks, Here's Why Accolade (ACCD) Looks Ripe for a Turnaround

Here's Why Accolade (ACCD) is Poised for a Turnaround After Losing -36.43% in 4 Weeks

Employer survey: 25% of employers currently offer coverage and most experience positive outcomes; 4 in 10 consider it an immediate concern and intend to offer in 2024; while 21% of HR decision-makers are unaware of GLP-1 medications.1 SEATTLE , Oct. 9, 2023 /PRNewswire/ -- Accolade (Nasdaq: ACCD) announced today findings from an employer survey on sentiment and adoption of GLP-1 medications. A key finding: while 81% of human resource (HR) decision-makers feel that their employees would be interested, only 25% cover GLP-1s today.

GLP-1 Coverage in Employer Plans Could Nearly Double in 2024

While Accolade increased revenue year over year, it is still losing money. Several analysts downgraded their price targets for the stock.

Why Shares of Accolade Fell This Week

Accolade, Inc. (NASDAQ:ACCD ) Q2 2024 Earnings Conference Call October 4, 2023 4:30 PM ET Company Participants Todd Friedman - Senior Vice President, Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Executive Vice President, Care Delivery and Chief Health Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Jessica Tassan - Piper Sandler Jailendra Singh - Truist Securities Jared Haase - William Blair Glen Santangelo - Jefferies Allen Lutz - Bank of America David Larsen - BTIG Stan Berenshteyn - Wells Fargo Robert Simmons - D.A. Davidson Jack Wallace - Guggenheim Partners John Penny - Canaccord Genuity Ryan MacDonald - Needham and Company Operator Good day, and thank you for standing by, and welcome to Accolade Second Quarter 2024 Earnings Results Conference Call.

Accolade, Inc. (ACCD) Q2 2024 Earnings Call Transcript

SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August 31, 2023.

Accolade Announces Results for Fiscal Second Quarter 2024

Accolade is in a good position to meet its revenue growth guidance for both the current fiscal year and long term. There is a risk that ACCD's bottom line could fall short of expectations in subsequent quarters, and investors might be concerned about Accolade's path to profitability for the long run. I rate ACCD stock as a Hold, following my evaluation of the company's revenue growth and profitability for the future.

Accolade: Consider Both Growth And Profitability

SEATTLE, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal second quarter 2024 financial results on Wednesday, October 4, 2023, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Accolade to Announce Fiscal Second Quarter 2024 Financial Results

Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE , Sept. 18, 2023 /PRNewswire/ -- Accolade (Nasdaq: ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy.

Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience

SEATTLE, Sept. 06, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Sept. 5, 2023 by Accolade, Inc. (NASDAQ: ACCD), please note that in the second bullet, the time of the Morgan Stanley presentation should be 1:35 pm ET, not 8:10 am ET as previously stated. The corrected release follows:

CORRECTING and REPLACING -- Accolade To Present at Upcoming Investor Conferences

HELSINKI--(BUSINESS WIRE)-- #MEC--FusionLayer Inc. has been featured as one of the top Edge Computing companies to watch in 2023 in the latest edition of Insights Success magazine. With an impressive portfolio of 33 secured patents in major economies worldwide, FusionLayer offers unparalleled visibility, scalability, and continuity across private data centers, public clouds, and emerging multi-access edge clouds. “FusionLayer technologies have enabled some of the most advanced telecoms and enterprises.

Named as a Top Edge Computing Company to Watch in 2023: FusionLayer Receives an Accolade for Its Hybrid Edge Networking Vision

CRISPR Therapeutics

Intellia Therapeutics

Invitae

Recursion Pharmaceuticals

Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.

News for Accolade Stock (ACCD)